S&P 500   4,580.18 (+0.63%)
DOW   35,679.97 (+0.53%)
QQQ   382.25 (+0.59%)
AAPL   151.45 (+1.75%)
MSFT   321.57 (-0.50%)
FB   309.54 (-0.86%)
GOOGL   2,908.27 (-0.55%)
TSLA   1,059.80 (+2.11%)
AMZN   3,389.41 (-0.09%)
NVDA   245.76 (+0.51%)
BABA   167.80 (-0.85%)
NIO   39.43 (+0.31%)
CGC   12.94 (+1.25%)
GE   103.43 (-0.40%)
AMD   120.75 (-1.25%)
MU   70.03 (+2.62%)
T   25.53 (+1.88%)
F   17.46 (+12.57%)
ACB   6.93 (+1.32%)
DIS   169.38 (-0.10%)
PFE   43.53 (+1.30%)
BA   206.90 (+0.14%)
AMC   35.34 (+1.67%)
S&P 500   4,580.18 (+0.63%)
DOW   35,679.97 (+0.53%)
QQQ   382.25 (+0.59%)
AAPL   151.45 (+1.75%)
MSFT   321.57 (-0.50%)
FB   309.54 (-0.86%)
GOOGL   2,908.27 (-0.55%)
TSLA   1,059.80 (+2.11%)
AMZN   3,389.41 (-0.09%)
NVDA   245.76 (+0.51%)
BABA   167.80 (-0.85%)
NIO   39.43 (+0.31%)
CGC   12.94 (+1.25%)
GE   103.43 (-0.40%)
AMD   120.75 (-1.25%)
MU   70.03 (+2.62%)
T   25.53 (+1.88%)
F   17.46 (+12.57%)
ACB   6.93 (+1.32%)
DIS   169.38 (-0.10%)
PFE   43.53 (+1.30%)
BA   206.90 (+0.14%)
AMC   35.34 (+1.67%)
S&P 500   4,580.18 (+0.63%)
DOW   35,679.97 (+0.53%)
QQQ   382.25 (+0.59%)
AAPL   151.45 (+1.75%)
MSFT   321.57 (-0.50%)
FB   309.54 (-0.86%)
GOOGL   2,908.27 (-0.55%)
TSLA   1,059.80 (+2.11%)
AMZN   3,389.41 (-0.09%)
NVDA   245.76 (+0.51%)
BABA   167.80 (-0.85%)
NIO   39.43 (+0.31%)
CGC   12.94 (+1.25%)
GE   103.43 (-0.40%)
AMD   120.75 (-1.25%)
MU   70.03 (+2.62%)
T   25.53 (+1.88%)
F   17.46 (+12.57%)
ACB   6.93 (+1.32%)
DIS   169.38 (-0.10%)
PFE   43.53 (+1.30%)
BA   206.90 (+0.14%)
AMC   35.34 (+1.67%)
S&P 500   4,580.18 (+0.63%)
DOW   35,679.97 (+0.53%)
QQQ   382.25 (+0.59%)
AAPL   151.45 (+1.75%)
MSFT   321.57 (-0.50%)
FB   309.54 (-0.86%)
GOOGL   2,908.27 (-0.55%)
TSLA   1,059.80 (+2.11%)
AMZN   3,389.41 (-0.09%)
NVDA   245.76 (+0.51%)
BABA   167.80 (-0.85%)
NIO   39.43 (+0.31%)
CGC   12.94 (+1.25%)
GE   103.43 (-0.40%)
AMD   120.75 (-1.25%)
MU   70.03 (+2.62%)
T   25.53 (+1.88%)
F   17.46 (+12.57%)
ACB   6.93 (+1.32%)
DIS   169.38 (-0.10%)
PFE   43.53 (+1.30%)
BA   206.90 (+0.14%)
AMC   35.34 (+1.67%)
Positive News Sentiment  
NASDAQ:CRDL

Cardiol Therapeutics Stock Forecast, Price & News

$4.07
+0.01 (+0.25 %)
(As of 10/28/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.01
▼
$4.14
50-Day Range
$2.90
▼
$4.80
52-Week Range
$1.82
▼
$4.96
Volume
751 shs
Average Volume
267,785 shs
Market Capitalization
$176.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive CRDL News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Cardiol Therapeutics logo

About Cardiol Therapeutics

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company that focuses on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its product, CardiolRx, is a pharmaceutically produced extra strength oral cannabidiol formulation that is entering a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Headlines

Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis
October 25, 2021 |  finance.yahoo.com
Traders Purchase High Volume of Cardiol Therapeutics Call Options (NASDAQ:CRDL)
October 15, 2021 |  americanbankingnews.com
Cardiol Therapeutics (NASDAQ:CRDL) Stock Price Up 4.3%
October 12, 2021 |  americanbankingnews.com
Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
September 16, 2021 |  finance.yahoo.com
Stocks in play: Cardiol Therapeutics Inc.
August 26, 2021 |  ca.finance.yahoo.com
Cardiol Therapeutics Inc. Class A
August 26, 2021 |  realmoney.thestreet.com
Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis
August 24, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
N/A
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRDL
Previous Symbol
CUSIP
N/A
CIK
1702123
Web
N/A
Phone
(289) 910-0850
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.27
Quick Ratio
12.27

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
43,332,000
Free Float
N/A
Market Cap
$176.36 million
Next Earnings Date
11/15/2021 (Estimated)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank™

Overall MarketRank™

1.63 out of 5 stars

Medical Sector

970th out of 1,372 stocks

Analyst Opinion: 2.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Cardiol Therapeutics (NASDAQ:CRDL) Frequently Asked Questions

Is Cardiol Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiol Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cardiol Therapeutics stock.
View analyst ratings for Cardiol Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Cardiol Therapeutics?

Wall Street analysts have given Cardiol Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cardiol Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cardiol Therapeutics' next earnings date?

Cardiol Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Cardiol Therapeutics.

How were Cardiol Therapeutics' earnings last quarter?

Cardiol Therapeutics Inc (NASDAQ:CRDL) issued its quarterly earnings data on Monday, August, 16th. The company reported ($0.13) earnings per share (EPS) for the quarter. The business had revenue of $0.06 million for the quarter.
View Cardiol Therapeutics' earnings history.

What price target have analysts set for CRDL?

2 Wall Street analysts have issued 12 month price targets for Cardiol Therapeutics' shares. Their forecasts range from $5.00 to $5.00. On average, they expect Cardiol Therapeutics' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 23.2% from the stock's current price.
View analysts' price targets for Cardiol Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Cardiol Therapeutics' key executives?

Cardiol Therapeutics' management team includes the following people:
  • David G. Elsley, President, Chief Executive Officer & Director
  • Bernard Lim, Chief Operating Officer
  • Christopher J. Waddick, Chief Financial Officer & Secretary
  • Dan Crandall, Finance Director
  • Anthony E. Bolton, Director of Research

What is Cardiol Therapeutics' stock symbol?

Cardiol Therapeutics trades on the NASDAQ under the ticker symbol "CRDL."

How do I buy shares of Cardiol Therapeutics?

Shares of CRDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardiol Therapeutics' stock price today?

One share of CRDL stock can currently be purchased for approximately $4.06.

How much money does Cardiol Therapeutics make?

Cardiol Therapeutics has a market capitalization of $175.93 million.

How can I contact Cardiol Therapeutics?

The company can be reached via phone at (289) 910-0850.


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.